Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
- - INCLUSION CRITERIA: - Measurable metatstatic unresectable malignancy expressing G12V mutated KRAS as assessed by one of the following methods: RT-PCR on tumor tissue, tumor DNA sequencing or any other CLIA certified laboratory test on resected tissue. Patients shown to have tumors expressing G12V mutated NRAS and HRAS will also be eligible as these oncogenes share complete amino acid homology with G12V mutated KRAS for their first 80 N-terminal amino acids, completely encompassing the target epitope. - Patients must be HLA-A*11:01 positive as confirmed by the NIH Department of Transfusion Medicine. - Confirmation of the diagnosis of cancer by the Laboratory of Pathology of the NCI. - Patients must: - have previously received standard systemic therapy for their advanced cancer and have been either non-responders or have recurred. Specifically: - For patients with metastatic colorectal cancer, they must have had at least two systemic chemotherapy regimens that include 5FU, leucovorin, bevacizumab, oxaliplatin and irinotecan (or similar agents) or have contraindications to receiving those medications. - Patients with pancreatic cancer must have received gemcitabine, 5FU, and oxaliplatin (or similar agents), or have contraindications to receiving those medications. - Patients with non-small cell lung cancer (NSCLC) must have had appropriate targeted therapy as indicated by abnormalities in ALK, EGFR or expression of PDL- 1. Other patients must have had platinum-based chemotherapy. - Patients with ovarian cancer or prostate cancer must have had approved first line chemotherapy OR - have declined standard treatment - Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and asymptomatic are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for 1 month after treatment for the patient to be eligible. Patients with surgically resected brain metastases are eligible. - Age greater than or equal to 18 years and less than or equal to 70 years. - Clinical performance status of ECOG 0 or 1 - Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment. - Serology: - Seronegative for HIV antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune-competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities.) - Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative. - Hematology: - ANC greater than or equal to 1000/mm^3 without the support of filgrastim - WBC greater than or equal to 3000/mm^3 - Platelet count greater than or equal to 100,000/mm^3 - Hemoglobin > 8.0 g/dL - Chemistry: - Serum ALT/AST less than or equal to 5.0 x ULN - Total bilirubin less tha or equal to 1.5 mg/dL, except in patients with Gilbert s Syndrome who must have a total bilirubin less than or equal to 3.0 mg/dL. - Patients must have either an eGFR > 60 mL/m (based on serum creatinine and lab nomogram) or a formal 6-24h CrCl > 60 mL/m. - More than four weeks must have elapsed since completion of any prior systemic therapy and enrollment. Note: Patients may have undergone minor surgical procedures or limited field radiotherapy within the four weeks before enrollment, as long as related major organ toxicities have recovered to grade 1 or less. - Ability of subject to understand and the willingness to sign a written informed consent document. - Willing to sign a durable power of attorney. - Subjects must be co-enrolled on NCI-SB cell harvest protocol 03-C-0277 (Cell Harvest and Preparation for Surgery Branch Adoptive Cell Therapy Protocols). EXCLUSION CRITERIA: 1. Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant. 2. Concurrent systemic steroid therapy. 3. Active systemic infections requiring anti-infective treatment, coagulation disorders, or any other active or uncompensated major medical illnesses. 4. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease). 5. Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities). 6. History of severe immediate hypersensitivity reaction to cyclophosphamide, aldesleukin, or fludarabine. 7. History of coronary revascularization or ischemic symptoms 8. Documented LVEF less than or equal to 45% tested in patients: - Age greater than or equal to 65 years - With clinically significant atrial and/or ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, second or third degree heart block or have a history of ischemic heart disease and/or chest pain 9. Documented FEV1 less than or equal to 50% predicted tested in patients with: - A prolonged history of cigarette smoking (approximately 20 packs/year within the past two years). - Symptoms of respiratory dysfunction 10. Patients who are receiving any other investigational agents
- We generated an HLA-A*11:01-restricted murine T-cell receptor (mTCR) that specifically
recognizes the G12V-mutated variant of KRAS (and other RAS family genes), expressed by
many human cancers and constructed a single retroviral vector that contains its alpha
and beta chains that confers recognition of this antigen when transduced into PBL.
- In co-cultures with HLA-A*11:01+ target cells expressing this mutated oncogene, mTCR
transduced T cells lyse target cells and secrete IFN-gamma with high specificity.
- Phase I: determine the safety of administering PBL transduced with anti-KRAS G12V mTCR
in concert with preparative lymphodepletion and high dose interleukin-2 (IL-2;
- Phase II:To determine if anti-KRAS G12V mTCR-transduced PBL can mediate the regression
of tumors harboring the RAS G12V mutation.
Patients must be/have:
- Age greater than or equal to 18 years and less than or equal to 70 years
- HLA-A*11:01 positive
- Metastatic or unresectable RAS G12V-expressing cancer which has progressed after
standard therapy (if available).
Patients may not have:
-Allergies or hypersensitivities to high-dose aldesleukin, cyclophosphamide or fludarabine.
- This is a Phase I/II, single center study of PBL transduced with anti-KRAS G12V mTCR in
HLA-A*11:01 positive patients with advanced solid tumors expressing G12V mutated RAS.
- PBMC obtained by leukapheresis will be cultured in the presence of anti-CD3 (OKT3) and
aldesleukin in order to stimulate T-cell growth.
- Transduction is initiated by exposure of these cells to retroviral vector supernatant
containing replication-incompetent virus encoding the anti-KRAS G12V mTCR.
- All patients will receive a non-myeloablative, lympho-depleting preparative regimen of
cyclophosphamide and fludarabine.
- On day 0 patients will receive their PBL transduced with the anti-KRAS G12V mTCR and
will then begin high-dose aldesleukin.
- A complete evaluation of lesions will be conducted approximately 6 weeks (+/- 2 weeks)
- The study will be conducted using a phase I/II Simon minimax design, with two separate
cohorts for the Phase II component: Cohort 2a, patients with RAS G12V pancreatic
cancer, and Cohort 2b, patients with RAS G12V non-pancreatic cancer.
-A total of 110 patients may be required; approximately 24 patients in the phase I portion of
the study and 86 (41, plus an allowance of up to 2 non-evaluable per phase II cohort)
patients in the phase II portion of the study.
Trial Phase Phase I/II
Trial Type Treatment
National Cancer Institute
James Chung-Yin Yang
- Primary ID 170113
- Secondary IDs NCI-2018-03522, 17-C-0113, NCI-2017-01108
- Clinicaltrials.gov ID NCT03190941